DUBLIN--(BUSINESS WIRE)--The "RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global RNA interference (RNAi) drug delivery market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the global RNA interference (RNAi) drug delivery market to grow at a CAGR of 22.8% during 2021-2026.
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- CureVac AG
- Dicerna Pharmaceuticals Inc.
- Gradalis Inc.
- Ionis Pharmaceuticals Inc
- Merck & Co. Inc.
- Moderna Inc.
- Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Silence Therapeutics PLC
- Sirnaomics Inc.
Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.
The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens.
Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Questions Answered in This Report
- How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
- What are the key regional markets?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the technology?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
4.2 Key Industry Trends
5 Global RNA Interference (RNAi) Drug Delivery Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Application
7 Market Breakup by Technology
8 Market Breakup by Region
9 SWOT Analysis
10 Value Chain Analysis
11 Porters Five Forces Analysis
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
For more information about this report visit https://www.researchandmarkets.com/r/8mngyr